Obesity Clinical Trials in Walnut Creek, California
11 studies are recruiting for obesity in Walnut Creek, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…
- Stage
- Phase 2
- Ages
- 18 to 75
- Site
- Diablo Clinical Research /ID# 282530, Walnut Creek, California
- Locations
- 45 in total
- Run by
- AbbVie
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…
- Stage
- Phase 2
- Ages
- 18 to 75
- Site
- Diablo Clinical Research, Inc., Walnut Creek, California
- Locations
- 56 in total
- Run by
- Eli Lilly and Company
-
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Diablo Clinical Research, Inc., Walnut Creek, California
- Locations
- 157 in total
- Run by
- Eli Lilly and Company
-
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Diablo Clinical Research, Inc., Walnut Creek, California
- Locations
- 74 in total
- Run by
- Novo Nordisk A/S
-
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Diablo Clinical Research, Inc., Walnut Creek, California
- Locations
- 50 in total
- Run by
- Pfizer
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
- Stage
- Phase 3
- Ages
- 45 to 99
- Site
- Diablo Clinical Research, Walnut Creek, California
- Locations
- 783 in total
- Run by
- Amgen
-
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).
- Stage
- Phase 3
- Ages
- 18 to 99
- Site
- Diablo Clinical Research, Walnut Creek, California
- Locations
- 87 in total
- Run by
- Amgen
-
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eit…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Flourish Research - CA, Walnut Creek, California
- Locations
- 303 in total
- Run by
- Novo Nordisk A/S
-
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …
- Stage
- Phase 2
- Ages
- 18 to 75
- Site
- Diablo Clinical Research, Inc., Walnut Creek, California
- Locations
- 40 in total
- Run by
- Eli Lilly and Company
-
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the …
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Diablo Clinical Research, Inc., Walnut Creek, California
- Locations
- 82 in total
- Run by
- Novo Nordisk A/S
-
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being …
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Diablo Clinical Research, Inc., Walnut Creek, California
- Locations
- 11 in total
- Run by
- Novo Nordisk A/S
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.